The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer

• Published in: Cancers Vol. 16; no. 2; p. 286
• Main Authors: Dennehy, Colum, Khan, Alisha F, Zaidi, Ali H, Lam, Vincent K
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: Adjuvant treatment; Cancer; Cancer therapies; Chemotherapy; Clinical trials; Development and progression; Drug therapy; Esophageal cancer; esophagogastric cancer; Gastric cancer; Immune checkpoint inhibitors; Immune system; Immunosuppressive agents; Immunotherapy; Invasiveness; Ipilimumab; localized; Monoclonal antibodies; Mortality; Oncology; Oncology, Experimental; Patients; perioperative; Prevention; Radiation; Radiation therapy; Standard of care; Surgery; Survival; Tumors; esophagogastric cancer; resectable; perioperative; esophageal cancer; gastric cancer; adjuvant; immunotherapy; localized; neo-adjuvant
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16020286

Despite advances in treatment strategies and surgical approaches in recent years, improving survival outcomes in esophagogastric cancer (EGC) patients treated with curative intent remains a significant area of unmet need. The recent emergence of adjuvant immunotherapy as the standard of care for resected EGC demonstrates the impact of immunotherapy in improving recurrence-free survival. Neoadjuvant and perioperative immunotherapies represent another promising approach with potential advantages over adjuvant therapy. Despite the promising results of early neoadjuvant immunotherapy studies, there are several challenges and future research needs. The optimal timing, duration and number of doses in relation to surgery and the optimal combination of immunotherapies are still unclear. In addition, rigorous correlative studies need to be performed to identify biomarkers for patient selection and treatment response prediction to maximize the benefits of neoadjuvant immunotherapy. In this review, we provide a concise summary of the current standard of care for resectable EGC and discuss the rationale for the use of immune checkpoint inhibitors in this setting and the pre-clinical and early clinical data of these novel therapies. Finally, we will examine the potential role and future direction of immunotherapy in the treatment paradigm and the perceived challenges and opportunities that lay ahead.